Top

International Journal of Clinical Oncology

Published in:

01-06-2016 | Invited Review Article

Basics of PD-1 in self-tolerance, infection, and cancer immunity

Author: Shunsuke Chikuma

Published in: International Journal of Clinical Oncology | Issue 3/2016

Abstract

Successful cancer treatment requires understanding host immune response against tumor cells. PD-1 belongs to the CD28 superfamily of receptors that work as “checkpoints” of immune activation. PD-1 maintains immune self-tolerance to prevent autoimmunity and controls T-cell reaction during infection to prevent excessive tissue damage. Tumor cells that arise from normal tissue acquire mutations that can be targeted by lymphocytes. Accumulating lines of evidence suggest that tumor cells evade host immune attack by expressing physiological PD-1 ligands and stimulating PD-1 on the lymphocytes. Based on this idea, researchers have successfully demonstrated that systemic administration of monoclonal antibodies that inhibit the binding of PD-1 to the ligands reactivated T cells and augmented the anti-cancer immune response. In this review, I summarize the basics of T-cell biology and its regulation by PD-1 and discuss the current understanding and questions about this multifaceted molecule.

Lenschow DJ, Walunas TL, Bluestone JA (1996) CD28/B7 system of T cell costimulation. Annu Rev Immunol 14:233–258CrossRefPubMed

Bour-Jordan H, Esensten JH, Martinez-Llordella M et al (2011) Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/B7 family. Immunol Rev 241:180–205CrossRefPubMedPubMedCentral

Krummel MF, Allison JP (1995) CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 182:459–465CrossRefPubMed

Walunas TL et al (1994) CTLA-4 can function as a negative regulator of T cell activation. Immunity 1:405–413CrossRefPubMed

Tivol EA, Borriello F, Schweitzer AN et al (1995) Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3:541–547CrossRefPubMed

Waterhouse P et al (1995) Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270:985–988CrossRefPubMed

Chambers CA, Cado D, Truong T et al (1997) Thymocyte development is normal in CTLA-4-deficient mice. Proc Natl Acad Sci USA 94:9296–9301CrossRefPubMedPubMedCentral

Greenwald RJ, Freeman GJ, Sharpe AH (2005) The B7 family revisited. Annu Rev Immunol 23:515–548CrossRefPubMed

Ishida Y, Agata Y, Shibahara K et al (1992) Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11:3887–3895PubMedPubMedCentral

10.

Agata Y et al (1996) Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 8:765–772CrossRefPubMed

11.

Chikuma S et al (2009) PD-1-mediated suppression of IL-2 production induces CD8+ T cell anergy in vivo. J Immunol 182:6682–6689CrossRefPubMed

12.

Nishimura H et al (1996) Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes. Int Immunol 8:773–780CrossRefPubMed

13.

McKay JT et al (2015) PD-1 suppresses protective immunity to Streptococcus pneumoniae through a B cell-intrinsic mechanism. J Immunol 194:2289–2299CrossRefPubMedPubMedCentral

14.

Freeman GJ et al (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:1027–1034CrossRefPubMedPubMedCentral

15.

Dong H, Zhu G, Tamada K et al (1999) B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 5:1365–1369CrossRefPubMed

16.

Latchman Y et al (2001) PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2:261–268CrossRefPubMed

17.

Tseng SY et al (2001) B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 193:839–846CrossRefPubMedPubMedCentral

18.

Yamazaki T et al (2002) Expression of programmed death 1 ligands by murine T cells and APC. J Immunol 169:5538–5545CrossRefPubMed

19.

Loke P, Allison JP (2003) PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci USA 100:5336–5341CrossRefPubMedPubMedCentral

20.

Romberg N et al (2013) Gain-of-function STAT1 mutations are associated with PD-L1 overexpression and a defect in B-cell survival. J Allergy Clin Immunol 131:1691–1693CrossRefPubMedPubMedCentral

21.

Liang SC et al (2003) Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol 33:2706–2716CrossRefPubMed

22.

Lucas JA, Menke J, Rabacal WA et al (2008) Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice. J Immunol 181:2513–2521CrossRefPubMedPubMedCentral

23.

Latchman YE et al (2004) PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci USA 101:10691–10696CrossRefPubMedPubMedCentral

24.

Keir ME et al (2006) Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 203:883–895CrossRefPubMedPubMedCentral

25.

Nishimura H, Nose M, Hiai H et al (1999) Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11:141–151CrossRefPubMed

26.

Nishimura H et al (2001) Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291:319–322CrossRefPubMed

27.

Okazaki T et al (2003) Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 9:1477–1483CrossRefPubMed

28.

Wang J, Yoshida T, Nakaki F et al (2005) Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. Proc Natl Acad Sci USA 102:11823–11828CrossRefPubMedPubMedCentral

29.

Wang J et al (2010) PD-1 deficiency results in the development of fatal myocarditis in MRL mice. Int Immunol 22:443–452CrossRefPubMed

30.

Okazaki T, Maeda A, Nishimura H et al (2001) PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci USA 98:13866–13871CrossRefPubMedPubMedCentral

31.

Parry RV et al (2005) CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 25:9543–9553CrossRefPubMedPubMedCentral

32.

Yokosuka T, Takamatsu M, Kobayashi-Imanishi W et al (2012) Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med 209:1201–1217CrossRefPubMedPubMedCentral

33.

Tsushima F et al (2007) Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. Blood 110:180–185CrossRefPubMedPubMedCentral

34.

Fife BT et al (2006) Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med 203:2737–2747CrossRefPubMedPubMedCentral

35.

Fife BT et al (2009) Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol 10:1185–1192CrossRefPubMedPubMedCentral

36.

Rui Y, Honjo T, Chikuma S (2013) Programmed cell death 1 inhibits inflammatory helper T-cell development through controlling the innate immune response. Proc Natl Acad Sci USA 110:16073–16078CrossRefPubMedPubMedCentral

37.

Iwai Y, Terawaki S, Ikegawa M et al (2003) PD-1 inhibits antiviral immunity at the effector phase in the liver. J Exp Med 198:39–50CrossRefPubMedPubMedCentral

38.

Barber DL et al (2006) Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439:682–687CrossRefPubMed

39.

Horne-Debets JM et al (2013) PD-1 dependent exhaustion of CD8+ T cells drives chronic malaria. Cell Rep 5:1204–1213CrossRefPubMed

40.

Lazar-Molnar E et al (2010) Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis. Proc Natl Acad Sci USA 107:13402–13407CrossRefPubMedPubMedCentral

41.

Barber DL, Mayer-Barber KD, Feng CG et al (2011) CD4 T cells promote rather than control tuberculosis in the absence of PD-1-mediated inhibition. J Immunol 186:1598–1607CrossRefPubMed

42.

Tousif S, Singh Y, Prasad DV et al (2011) T cells from Programmed Death-1 deficient mice respond poorly to Mycobacterium tuberculosis infection. PLoS One 6:e19864CrossRefPubMedPubMedCentral

43.

Odorizzi PM, Pauken KE, Paley MA et al (2015) Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells. J Exp Med 212:1125–1137CrossRefPubMedPubMedCentral

44.

Honda T, Egen JG, Lammermann T et al (2014) Tuning of antigen sensitivity by T cell receptor-dependent negative feedback controls T cell effector function in inflamed tissues. Immunity 40:235–247CrossRefPubMedPubMedCentral

45.

Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734–1736CrossRefPubMed

46.

Thompson RH et al (2004) Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA 101:17174–17179CrossRefPubMedPubMedCentral

47.

Wu C, Zhu Y, Jiang J et al (2006) Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem 108:19–24CrossRefPubMed

48.

Nakanishi J, Wada Y, Matsumoto K et al (2007) Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother 56:1173–1182CrossRefPubMed

49.

Hamanishi J et al (2007) Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 104:3360–3365CrossRefPubMedPubMedCentral

50.

Hino R et al (2010) Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 116:1757–1766CrossRefPubMed

51.

Iwai Y, Ishida M, Tanaka Y et al (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99:12293–12297CrossRefPubMedPubMedCentral

52.

Curiel TJ et al (2003) Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 9:562–567CrossRefPubMed

53.

Brahmer JR et al (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28:3167–3175CrossRefPubMedPubMedCentral

54.

Brahmer JR et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455–2465CrossRefPubMedPubMedCentral

55.

Topalian SL et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454CrossRefPubMedPubMedCentral

56.

Terawaki S et al (2011) IFN-alpha directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J Immunol 186:2772–2779CrossRefPubMed

57.

Wolchok JD et al (2013) Nivolumab plus Ipilimumab in Advanced Melanoma. N Engl J Med 2013:2

58.

Okazaki T, Chikuma S, Iwai Y et al (2013) A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol 14:1212–1218CrossRefPubMed

59.

Hughes J et al (2015) Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care 38:e55–57CrossRefPubMedPubMedCentral

60.

Martin-Liberal J, Furness AJ, Joshi K et al (2015) Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report. Cancer Immunol Immunother 64:765–767CrossRef

61.

Loochtan AI, Nickolich MS, Hobson-Webb LD (2015) Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer. Muscle Nerve 52:307–308CrossRefPubMed

Title: Basics of PD-1 in self-tolerance, infection, and cancer immunity
Author: Shunsuke Chikuma
Publication date: 01-06-2016
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 3/2016
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-016-0958-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2016

Secondary cancers after a childhood cancer diagnosis: a nationwide hospital-based retrospective cohort study in Japan

Characterization of mild and severe post-radical nephrectomy renal functional deterioration utilizing histopathological evaluation of non-neoplastic nephrectomized renal parenchyma

Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin

Preoperative predictive factors and further risk stratification of biochemical recurrence in clinically localized high-risk prostate cancer

Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin

Age-based disparities in treatment and outcomes of retroperitoneal rhabdomyosarcoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer